Aytu BioPharma, Inc. (NASDAQ:AYTU) Short Interest Update

Aytu BioPharma, Inc. (NASDAQ:AYTU) saw a significant decrease in short interest in November. As of November 15th, there was short interest totalling 120,800 shares, a decrease of 37.3% from the October 31st total of 192,800 shares. Currently, 2.0% of the company’s shares are sold short. Based on an average daily trading volume, of 29,500 shares, the days-to-cover ratio is currently 4.1 days.

Institutional Trading of Aytu BioPharma

A number of hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP raised its position in Aytu BioPharma by 54.5% during the second quarter. Dimensional Fund Advisors LP now owns 23,551 shares of the company’s stock valued at $69,000 after buying an additional 8,311 shares during the period. Armistice Capital LLC acquired a new stake in Aytu BioPharma during the 2nd quarter worth about $736,000. Finally, Stonepine Capital Management LLC grew its stake in Aytu BioPharma by 6.0% during the 3rd quarter. Stonepine Capital Management LLC now owns 500,958 shares of the company’s stock valued at $1,177,000 after acquiring an additional 28,489 shares in the last quarter. Hedge funds and other institutional investors own 33.49% of the company’s stock.

Aytu BioPharma Trading Down 0.6 %

Shares of AYTU traded down $0.01 during midday trading on Friday, hitting $1.61. The stock had a trading volume of 18,152 shares, compared to its average volume of 22,925. The business has a 50-day simple moving average of $2.02 and a two-hundred day simple moving average of $2.50. The firm has a market cap of $9.90 million, a P/E ratio of -1.31 and a beta of -1.40. The company has a current ratio of 0.99, a quick ratio of 0.80 and a debt-to-equity ratio of 0.35. Aytu BioPharma has a fifty-two week low of $1.41 and a fifty-two week high of $3.45.

Aytu BioPharma (NASDAQ:AYTU) last issued its quarterly earnings results on Thursday, September 26th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.37). Aytu BioPharma had a negative net margin of 8.28% and a negative return on equity of 21.89%. The firm had revenue of $17.98 million during the quarter.

About Aytu BioPharma

Aytu Biopharma, Inc, a commercial-stage pharmaceutical company, focuses on commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates through two segments: Rx segment and Consumer Health segment. The Rx segment offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years and older, and Cotempla XR-ODT for patients from six to seventeen years old.